Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Pise-Masison Website

Cynthia A. Pise-Masison, Ph.D.

Selected Publications

1)  Liyanage NP, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, Schifanella L, Pise-Masison CA, Lipinska D, Grubczak K, Moniuszko M, Franchini G.
Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques.
Virology. 450-451: 359-68, 2014.
2)  Chevalier SA, Turpin J, Cachat A, Afonso PV, Gessain A, Brady JN, Pise-Masison CA, Mahieux R.
Gem-induced cytoskeleton remodeling increases cellular migration of HTLV-1-infected cells, formation of infected-to-target T-cell conjugates and viral transmission.
PLoS Pathog. 10: e1003917, 2014.
3)  Fenizia C, Fiocchi M, Jones K, Parks RW, Ceribelli M, Chevalier SA, Edwards D, Ruscetti F, Pise-Masison CA, Franchini G.
Human T-cell leukemia/lymphoma virus type 1 p30, but not p12/p8, counteracts toll-like receptor 3 (TLR3) and TLR4 signaling in human monocytes and dendritic cells.
J. Virol. 88: 393-402, 2014.
4)  Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Blood. 121: 2029-37, 2013.
5)  Chevalier SA, Durand S, Dasgupta A, Radonovich M, Cimarelli A, Brady JN, Mahieux R, Pise-Masison CA.
The transcription profile of Tax-3 is more similar to Tax-1 than Tax-2: insights into HTLV-3 potential leukemogenic properties.
PLoS ONE. 7: e41003, 2012.
6)  Edwards DC, McKinnon KM, Fenizia C, Jung KJ, Brady JN, Pise-Masison CA.
Inhibition of geranylgeranyl transferase-I decreases cell viability of HTLV-1-transformed cells.
Viruses. 3: 1815-35, 2011.
7)  Edwards D, Fenizia C, Gold H, de Castro-Amarante MF, Buchmann C, Pise-Masison CA, Franchini G.
Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence.
Viruses. 3: 861-85, 2011.
8)  Andresen V, Pise-Masison CA, Sinha-Datta U, Bellon M, Valeri V, Washington Parks R, Cecchinato V, Fukumoto R, Nicot C, Franchini G.
Suppression of HTLV-1 replication by Tax-mediated re-routing of the p13 viral protein to nuclear speckles.
Blood. 118: 1549-59, 2011.
9)  Van Prooyen N, Andresen V, Gold H, Bialuk I, Pise-Masison C, Franchini G.
Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.
Mol. Aspects Med. 31: 333-43, 2010.
10)  Cho WK, Jang MK, Huang K, Pise-Masison CA, Brady JN.
Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding.
J. Virol. 84: 12801-9, 2010.
11)  Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.
Cancer Cell. 16: 521-32, 2009.
12)  Zhou M, Huang K, Jung KJ, Cho WK, Klase Z, Kashanchi F, Pise-Masison CA, Brady JN.
Bromodomain protein Brd4 regulates human immunodeficiency virus transcription through phosphorylation of CDK9 at threonine 29.
J. Virol. 83: 1036-44, 2009.
13)  Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN.
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Blood. 113: 4016-26, 2009.
14)  Sakakibara S, Pise-Masison CA, Brady JN, Tosato G.
Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells.
J. Virol. 83: 2140-53, 2009.
15)  Pise-Masison CA, Marriott SJ.
Memories of John N. Brady: scientist, mentor and friend.
Retrovirology. 6: 48, 2009.
16)  Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ.
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
Cancer Res. 68: 5478-86, 2008.
17)  Chung HK, Pise-Masison CA, Radonovich MF, Brady J, Lee JK, Cheon SY, Markham P, Cristillo A, Pal R.
Cellular gene expression profiles in rhesus macaques challenged mucosally with a pathogenic R5 tropic simian human immunodeficiency virus isolate.
Viral Immunol. 21: 411-23, 2008.
18)  Couto FM, Minn AH, Pise-Masison CA, Radonovich M, Brady JN, Hanson M, Fernandez LA, Wang P, Kendziorski C, Shalev A.
Exenatide blocks JAK1-STAT1 in pancreatic beta cells.
Metab. Clin. Exp. 56: 915-8, 2007.
19)  Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, Brady JN, Udey MC, Vogel JC.
Characterization and isolation of stem cell-enriched human hair follicle bulge cells.
J. Clin. Invest. 116: 249-60, 2006.
20)  Jeong SJ, Lu H, Cho WK, Park HU, Pise-Masison C, Brady JN.
Coactivator-associated arginine methyltransferase 1 enhances transcriptional activity of the human T-cell lymphotropic virus type 1 long terminal repeat through direct interaction with Tax.
J. Virol. 80: 10036-44, 2006.
21)  Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ.
Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
Clin. Cancer Res. 12: 690-700, 2006.
22)  Welch KD, Reilly TP, Bourdi M, Hays T, Pise-Masison CA, Radonovich MF, Brady JN, Dix DJ, Pohl LR.
Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice.
Chem. Res. Toxicol. 19: 223-33, 2006.
23)  Chevalier SA, Meertens L, Pise-Masison C, Calattini S, Park H, Alhaj AA, Zhou M, Gessain A, Kashanchi F, Brady JN, Mahieux R.
The tax protein from the primate T-cell lymphotropic virus type 3 is expressed in vivo and is functionally related to HTLV-1 Tax rather than HTLV-2 Tax.
Oncogene. 25: 4470-82, 2006.
24)  Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN.
A novel NF-kappaB pathway involving IKKbeta and p65/RelA Ser-536 phosphorylation results in p53 Inhibition in the absence of NF-kappaB transcriptional activity.
J. Biol. Chem. 280: 10326-32, 2005.
25)  Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN.
Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells.
Oncogene. 24: 6719-28, 2005.
26)  Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ.
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Cancer Res. 65: 10602-12, 2005.
27)  Minn AH, Pise-Masison CA, Radonovich M, Brady JN, Wang P, Kendziorski C, Shalev A.
Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein.
Biochem. Biophys. Res. Commun. 336: 770-8, 2005.
28)  Kovanen PE, Young L, Al-Shami A, Rovella V, Pise-Masison CA, Radonovich MF, Powell J, Fu J, Brady JN, Munson PJ, Leonard WJ.
Global analysis of IL-2 target genes: identification of chromosomal clusters of expressed genes.
Int. Immunol. 17: 1009-21, 2005.
29)  Pise-Masison CA, Brady JN.
Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function.
Front. Biosci. 10: 919-30, 2005.
30)  Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, Berzofsky JA, Leonard WJ.
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
J. Exp. Med. 201: 139-48, 2005.
31)  Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA.
HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity.
Blood. 104: 1490-7, 2004.
32)  Pise-Masison CA, Jeong SJ, Brady JN.
Human T cell leukemia virus type 1: the role of Tax in leukemogenesis.
Arch. Immunol. Ther. Exp. (Warsz.). 53: 283-96, 2004.
33)  Lu H, Pise-Masison CA, Linton R, Park HU, Schiltz RL, Sartorelli V, Brady JN.
Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat.
J. Virol. 78: 6735-43, 2004.
34)  Meertens L, Pise-Masison C, Quere N, Brady J, Gessain A, Mahieux R.
Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition.
Oncogene. 23: 5447-58, 2004.
35)  Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ.
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.
Oncogene. 23: 8065-77, 2004.
36)  Chowdhury IH, Radonovich M, Mahieux R, Pise-Masison C, Muralidhar S, Brady JN.
P53 facilitates degradation of human T-cell leukaemia virus type I Tax-binding protein through a proteasome-dependent pathway.
J. Gen. Virol. 84: 897-906, 2003.
37)  Kelly JA, Spolski R, Kovanen PE, Suzuki T, Bollenbacher J, Pise-Masison CA, Radonovich MF, Lee S, Jenkins NA, Copeland NG, Morse HC, Leonard WJ.
Stat5 synergizes with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma.
J. Exp. Med. 198: 79-89, 2003.
38)  Lu H, Pise-Masison CA, Fletcher TM, Schiltz RL, Nagaich AK, Radonovich M, Hager G, Cole PA, Brady JN.
Acetylation of nucleosomal histones by p300 facilitates transcription from tax-responsive human T-cell leukemia virus type 1 chromatin template.
Mol. Cell. Biol. 22: 4450-62, 2002.
39)  Xue HH, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, Leonard WJ.
IL-2 negatively regulates IL-7 receptor alpha chain expression in activated T lymphocytes.
Proc. Natl. Acad. Sci. U.S.A. 99: 13759-64, 2002.
40)  Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM.
Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway.
Endocrinology. 143: 3695-8, 2002.
41)  Pise-Masison CA, Radonovich M, Mahieux R, Chatterjee P, Whiteford C, Duvall J, Guillerm C, Gessain A, Brady JN.
Transcription profile of cells infected with human T-cell leukemia virus type I compared with activated lymphocytes.
Cancer Res. 62: 3562-71, 2002.
42)  Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, Pise-Masison CA, Pohl LR.
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
Chem. Res. Toxicol. 14: 1620-8, 2001.
43)  Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C.
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.
Blood. 98: 3762-9, 2001.
44)  Reilly TP, Bourdi M, Brady JN, Pise-Masison CA, Radonovich MF, George JW, Pohl LR.
Expression profiling of acetaminophen liver toxicity in mice using microarray technology.
Biochem. Biophys. Res. Commun. 282: 321-8, 2001.
45)  Nicot C, Mahieux R, Pise-Masison C, Brady J, Gessain A, Yamaoka S, Franchini G.
Human T-cell lymphotropic virus type 1 Tax represses c-Myb-dependent transcription through activation of the NF-kappaB pathway and modulation of coactivator usage.
Mol. Cell. Biol. 21: 7391-402, 2001.
46)  Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN.
Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent.
J. Biol. Chem. 276: 200-5, 2001.
47)  Shalev A, Valásek L, Pise-Masison CA, Radonovich M, Phan L, Clayton J, He H, Brady JN, Hinnebusch AG, Asano K.
Saccharomyces cerevisiae protein Pci8p and human protein eIF3e/Int-6 interact with the eIF3 core complex by binding to cognate eIF3b subunits.
J. Biol. Chem. 276: 34948-57, 2001.
48)  Kashanchi F, Agbottah ET, Pise-Masison CA, Mahieux R, Duvall J, Kumar A, Brady JN.
Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.
J. Virol. 74: 652-60, 2000.
49)  Mahieux R, Pise-Masison CA, Lambert PF, Nicot C, De Marchis L, Gessain A, Green P, Hall W, Brady JN.
Differences in the ability of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 tax to inhibit p53 function.
J. Virol. 74: 6866-74, 2000.
50)  Mahieux R, Pise-Masison CA, Nicot C, Green P, Hall WW, Brady JN.
Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators.
AIDS Res. Hum. Retroviruses. 16: 1677-81, 2000.
51)  Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN.
Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.
Mol. Cell. Biol. 20: 3377-86, 2000.
52)  Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C, Brady JN.
Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax.
AIDS Res. Hum. Retroviruses. 16: 1669-75, 2000.
53)  Jiang H, Lu H, Schiltz RL, Pise-Masison CA, Ogryzko VV, Nakatani Y, Brady JN.
PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner.
Mol. Cell. Biol. 19: 8136-45, 1999.
54)  Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN.
Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein.
J. Virol. 72: 1165-70, 1998.
55)  Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN.
Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells.
J. Virol. 72: 6348-55, 1998.
56)  Dittmer J, Pise-Masison CA, Clemens KE, Choi KS, Brady JN.
Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter.
J. Biol. Chem. 272: 4953-8, 1997.
57)  Pise-Masison CA, Dittmer J, Clemens KE, Brady JN.
Physical and functional interaction between the human T-cell lymphotropic virus type 1 Tax1 protein and the CCAAT binding protein NF-Y.
Mol. Cell. Biol. 17: 1236-43, 1997.
58)  DiFronzo NL, Pise-Masison CA, Fernandez-Larsson R, Holland CA.
Viral determinants of HIV-1 sufficient to extend tropism to macrophages are distinct from the determinants that control the cytopathic phenotype in HL-60 cells.
AIDS. 11: 1681-8, 1997.
59)  Pise-Masison CA, Holland CA.
Restricted replication of the HIV-1 T-lymphotropic isolate NL4-3 in HL-60 cells.
Virology. 206: 641-5, 1995.
60)  Pise CA, Newburger PE, Holland CA.
Human immunodeficiency virus type 1-infected HL-60 cells are capable of both monocytic and granulocytic differentiation.
J. Gen. Virol. 73 ( Pt 12): 3257-61, 1992.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/10/2014.